Side by side

1. 1.MGF is a splice variant of IGF-1 produced in muscle after mechanical damage.
2. 2.In laboratory models it activates muscle stem cells and drives local repair.
3. 3.The PEGylated form is designed to survive enzyme breakdown long enough to act.
4. 4.Most effects described are local to the injected muscle, which is why users inject near the injury.
5. 5.These mechanisms have not been demonstrated in controlled human studies.

• Muscle repair and hypertrophy in animal and cell models
• Satellite cell activation research
• Injury-recovery claims in sports settings
• No human trials exist

• Local muscle growth in animal models
• Increased protein synthesis in laboratory tissue
• Reported faster injury recovery in user accounts
• Hypoglycaemia risk, as with the IGF-1 family

• Injection-site pain and swelling
• Hypoglycaemia
• Joint and jaw pain, as with the IGF-1 class
• Possible promotion of existing cancers
• Long-term safety unknown

Research context only — no human protocol exists. Laboratory work used microgram doses in cell and animal models. Schedules of 200–400 micrograms injected into a specific muscle after training come entirely from community practice, and there is no published human safety or efficacy data.

Research context only